Year: 2008
Type: letter
Abstract: We write in response to a recently published paper in this journal [1] in which mainly nondiabetic patients with renal impairment, without polypharmacy, were evaluated using exenatide.The study concluded that subjects with mild to moderate renal impairment were able to tolerate the drug.However, whether this is the case for patients with Type 2 diabetes remains uncertain, and we present a case that highlights potential problems.Exenatide 5 mg b.i.d. was given to one male patient (66 years, body mass index 35.1 kg m -2 ) with Type 2 diabetes since 1992,who in 1995 was diagnosed with microalbuminuria.By 1998 he had developed macroalbuminuria, in 2000 his creatinine levels exceeded upper limits of normal and in 2004 he had developed renal impairment-related anaemia and metabolic bone disease.Other complications were proliferative retinopathy (diagnosed 1995), peripheral sensory neuropathy (since 1996) and gout ( since 2007).Concomitant medications were losartan potassium 25 mg q.d., furosemide 40 mg b.i.d., spirinolactone 50 mg q.d., alfacalcidol 0.25 mg 3 days week -1 , darbepoetin alfa 20 mg month -1 , allopurinol 100 mg q.d., biphasic insulin aspart 30 b.i.d.[40-42 units (U) breakfast, 60-66 U dinner] and insulin aspart q.d.(10 U lunch).Due to non-optimal glycaemic control the patient was given exenatide (February 2008) after careful explanation that this was considered off-label use, since he was taking insulin.In the following 4 weeks the patient's creatinine levels rose (192 to 244 mmol l -1 ) and, correspondingly, the Cockroft-Gault [2] creatinine clearance (CrCL) was reduced (53.1 to 41.8 mg min -1 , Figure 1).Reductions were also seen in HbA1c, fasting plasma glucose (respectively 7.6 to 6.8% and 7.2 to 5.1 mmol l -1 ) and total daily insulin dosages (by 40%).The worsening of renal impairment was not related to urinary tract infection, obstruction or dehydration, although he experienced some nausea and diarrhoea.Hence, exenatide was stopped, and within the next 2 weeks his kidney function parameters returned to pretreatment levels (creatinine 196 mmol l -1 , CrCL 52.1 mg min -1 ).
Authors: Odd Erik Johansen, Rolf Whitfield
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: exenatide, renal dysfunction, type 2 diabetes, drug-induced nephrotoxicity, creatinine clearance, off-label drug use, microalbuminuria, macroalbuminuria, anemia of chronic kidney disease, metabolic bone disease, glycemic control, adverse drug reactions, DPP-4 inhibitors, GLP-1 receptor agonists
Open Access status: bronze
OpenAlex ID: W1975996626
